Intrinsic Value of S&P & Nasdaq Contact Us

SI-BONE, Inc. SIBN NASDAQ

NASDAQ Global Market • Healthcare • Medical - Devices • US • USD

SharesGrow Score
59/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$25.25
+75%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

SI-BONE, Inc. (SIBN) has a negative trailing P/E of -30.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 288.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.29%, forward earnings yield 0.35%. PEG 0.53 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (88/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.53); analyst target implies upside (+75%).
  • Forward P/E 288.6 — analysts expect a return to profitability with estimated EPS of $0.05 for FY2029.
  • PEG Ratio 0.53 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -3.29% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.35% as earnings recover.
  • Analyst consensus target $25.25 (+75% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 59/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score
59/100
SG Score
View full scorecard →
VALUE
88/100
Price-to-Earnings & upside
Proven by this page
FUTURE
100/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
~
MOAT
49/100
→ Income
GROWTH
100/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — SIBN

Valuation Multiples
P/E (TTM)-30.4
Forward P/E288.6
PEG Ratio0.53
Forward PEG0.53
P/B Ratio3.23
P/S Ratio2.90
EV/EBITDA-64.0
Per Share Data
EPS (TTM)$-0.43
Forward EPS (Est.)$0.05
Book Value / Share$4.08
Revenue / Share$4.62
FCF / Share$-0.21
Yields & Fair Value
Earnings Yield-3.29%
Forward Earnings Yield0.35%
Dividend Yield0.00%
Analyst Target$25.25 (+75%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -15.1 -1.10 -2.86 7.38 -
2017 -12.1 -0.49 -2.15 5.80 -
2018 -19.0 0.56 3.68 6.00 -
2019 -13.8 -0.25 8.43 7.89 -
2020 -19.9 1.55 5.13 11.84 -
2021 -13.0 -0.93 5.48 8.17 -
2022 -7.6 -1.62 4.73 4.37 -
2023 -18.6 0.50 4.76 5.81 -
2024 -18.8 0.56 3.48 3.48 -
2025 -45.4 1.10 4.83 4.27 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-1.33 $42.1M $-20.59M -48.9%
2017 $-1.66 $47.98M $-23.04M -48%
2018 $-1.10 $55.38M $-17.45M -31.5%
2019 $-1.72 $67.3M $-42.58M -63.3%
2020 $-1.67 $73.39M $-48.54M -66.1%
2021 $-1.81 $90.15M $-60.13M -66.7%
2022 $-1.84 $106.41M $-62.9M -59.1%
2023 $-1.13 $138.89M $-43.34M -31.2%
2024 $-0.75 $167.18M $-30.91M -18.5%
2025 $-0.44 $200.93M $-18.91M -9.4%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.51 $-0.56 – $-0.46 $230.5M $230.24M – $230.75M 6
2027 $-0.39 $-0.47 – $-0.33 $265.19M $264.53M – $265.83M 6
2028 $-0.26 $-0.27 – $-0.25 $306.01M $305.66M – $306.35M 2
2029 $0.05 $0.05 – $0.05 $350.2M $348.7M – $351.89M 1
2030 $0.32 $0.32 – $0.32 $400.1M $398.39M – $402.03M 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message